Business  
/
 
Sectors  
/
 
Health & Pharma
Michelle McIntosh, lead researcher of Monash Institute of Pharmaceutical Sciences, says her group plans to start testing a dry-powdered form of oxytocin by early 2014. Source: Monash University via Bloomberg Failed insulin drug technology may play key role in stemming maternal mortality

Companies working to deliver oxytocin by inhaler in Africa where one in 10 women suffer excessive bleeding after childbirth

Actavis to buy Warner Chilcott in $5 billion stock deal

Irish domicile of target company an attraction for generic drug maker

Cantillon: Hyperactive Elan betting that it can hold shareholders

Drugmaker seems a long way from the measured approach that has typified the tenure of Kelly Martin

Kelly Martin, chief executive of Elan, says the transactions will deliver long-term growth in income and value. Photograph: Alan Betson/The Irish Times Royalty ups Elan bid by 10%

Irish drugmaker announces two more deals plus plans to raise $800 million

One More Thing: May brings little cheer for Pfizer staff

Elan retains a royalty interest after selling its ownership of Tysabri to partner Biogen Idec for $3.25 billion. Elan urges shareholders to reject Royalty Pharma offer

Company says bid fails to properly value business

The Pfizer plant in Ringaskiddy: while yesterday’s announcement is good news, bolstering its production, it too is an old plant. Photograph: Provision Little hope for Little Island?

Cantillon: Success in selling redundant sites hides deeper shift in Irish pharma outlook

Ken Kelleher, chairman of the Little Island Community Association, outside Pfizer’s plant in Little Island, Cork, today. Photograph: Provision Pfizer announces closure of Little Island plant

Company cites falling demand for products as patents expire

Pfizer to close Little Island plant in Cork

Manufacturing moving to Ringaskiddy facility, says company

Economist Colm Mc Carthy, with Aviva Health Insurance chief executive Alison Burns, at the launch of his report on the future of the private health market, commissioned by Aviva. Colm McCarthy opposes private patient charge plan

Economist warns of 25 per cent rise in premiums if charges imposed in public hospitals

Elan chief executive Kelly Martin. The company has agreed a $1bn royalty deal with Theravance. Photo: Alan Betson/The Irish Times Elan to pay $1bn for Theravance stake

Irish pharmaceutical company agrees to buy 21% of royalty Theravance receives from GSK

Jazz shares hit a bad note

Fears over generic competition worry investors

Health Pharma

Michelle McIntosh, lead researcher of Monash Institute of Pharmaceutical Sciences, says her group plans to start testing a dry-powdered form of oxytocin by early 2014. Source: Monash University via Bloomberg Failed insulin drug technology may play key role in stemming maternal mortality
Actavis to buy Warner Chilcott in $5 billion stock deal
Kelly Martin, chief executive of Elan, says the transactions will deliver long-term growth in income and value. Photograph: Alan Betson/The Irish Times Royalty ups Elan bid by 10%